Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2023 Sep;38(5):641-650.
doi: 10.3904/kjim.2023.206. Epub 2023 Aug 28.

Korean guidelines for the management of gout

Jennifer Jooha Lee  1 , Ji Soo Lee  2 , Min Kyung Chung  2 , Joong Kyong Ahn  3 , Hyo-Jin Choi  4 , Seung-Jae Hong  5 , Chong-Hyeon Yoon  1 , Su-Hyun Kim  6 , Kyung-Hwan Jeong  7 , Jong-Woo Kim  8 , Bo-Yeon Kim  9 , Jin-Ho Shin  10 , Woo Gyu Kim  11 , Soo-Young Kim  12 , Hyun-Jung Kim  13 , Jeong-Soo Song  14 , Jae-Bum Jun  15 , Hyun-Ah Park  16 , Shung Chull Chae  17 , Bum Soon Choi  18 , Tae Nyun Kim  19 , Hyun Ah Kim  20
Affiliations
Guideline

Korean guidelines for the management of gout

Jennifer Jooha Lee et al. Korean J Intern Med. 2023 Sep.

Abstract

Gout is the most common form of arthritis, with the prevalence increasing worldwide. The present treatment guidelines provide recommendations for the appropriate treatment of acute gout, management during the inter-critical period, and prevention of chronic complications. The guidelines were developed based on evidence-based medicine and draft recommendations finalized after expert consensus. These guidelines are designed to provide clinicians with clinical evidence to enable efficient treatment of gout.

Keywords: Gout; Guidelines; Treatment.

PubMed Disclaimer

Conflict of interest statement

All members of the development committee disclosed their potential conflicts of interest before the start of the process. Members were asked whether they were hired by or consulted with any company or institution that could affect the guidelines. They were also asked whether they had stocks in or held intellectual properties of any drugs used in gout treatment or received honoraria from certain companies. We obtained signed documentation verifying that there were no conflicts of interest (Supplementary Material 5).

References

    1. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. - PMC - PubMed
    1. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408–14. - PubMed
    1. Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook. GRADE Working Group, 2013.
    1. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66:719–25. - PubMed
    1. Chung MK, Kim SS, Cheon YH, Hong SJ, Choi HJ, Seo MR, et al. Patient perspectives and preferences regarding gout and gout management: impact on adherence. J Korean Med Sci. 2021;36:e208. - PMC - PubMed

Publication types